Haemonetics (HAE) Common Equity (2010 - 2026)

Haemonetics' Common Equity history runs 17 years deep, the most recent figure standing at $796.3 million for Q1 2026.

• On a quarterly basis, Common Equity fell 2.99% year-over-year to $796.3 million in Q1 2026; TTM through Mar 2026 was $796.3 million, a 2.99% decrease from a year earlier, with the FY2026 full-year figure at $796.3 million, down 2.99% from the prior year.
• Common Equity fell to $796.3 million in Q1 2026 per HAE's latest filing, from $911.5 million in the prior quarter.
• Across five years, Common Equity topped out at $960.0 million in Q1 2024 and bottomed at $729.0 million in Q4 2022.
• The 5-year median for Common Equity is $856.9 million (2023), against an average of $843.7 million.
• Across the five-year window, Common Equity climbed 22.59% in 2023 and declined 14.49% in 2025, its largest moves.
• Year by year, Common Equity stood at $776.0 million in 2022, then advanced by 21.57% to $943.3 million in 2023, then slipped by 3.86% to $906.9 million in 2024, then rose by 0.51% to $911.5 million in 2025, then fell by 12.63% to $796.3 million in 2026.
• Per Business Quant, the three latest HAE Common Equity figures stand at $796.3 million (Q1 2026), $911.5 million (Q4 2025), and $849.2 million (Q3 2025).